XCancer

How to Navigate RLT Connect Distinguished Investigators Conferences Education RLT Components Sponsors Trial Stats

Adrenal Gland/Adrenocortical Basket Trials (Multiple Types)Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI)Bladder/Urothelial (GU)Bone Metastases Brain and Central Nervous System (CNS)Breast Cervical (GYN)Colon/Rectal/Anal (GI)Endocrine Cancers Endocrine Neoplasia Esophageal (GI)Gastric/Stomach (GI)Gastrointestinal (GI) (Multiple Types)General Solid Tumors (Multiple Types)GenitoUrinary (GU) (Multiple Types)GEP-NET (NEC)GI Stromal Tumor (GIST)Gynecologic (GYN) (Multiple Types)Head and Neck Cancers Hepatocellular/Liver (GI)Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU)Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types)NeuroEndocrine Carcinoma (NEC)Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN)Pancreatic (GI)Paraganglioma (NEC)Penile (GU)Pheochromocytoma (NEC)Pituitary Prostate (GU)Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU)Thymoma Thyroid Unknown Primary Cancers Uterine (GYN)Vulvar (GYN)

Filters

(1 results)

Keyword

Country

Isotope

Study Types

Imaging Treatment Treatment & Imaging

Sponsor

Enrolling Status

Enrolling On Hold Not Enrolling Unknown

Study Sponsor Type

Company Sponsored Investigator Sponsored Unsponsored

Theranostic Trials

Vulvar (GYN)

Adrenal Gland/Adrenocortical Basket Trials (Multiple Types)Biliary Tract/Gall Bladder/Cholangiocarcinoma (GI)Bladder/Urothelial (GU)Bone Metastases Brain and Central Nervous System (CNS)Breast Cervical (GYN)Colon/Rectal/Anal (GI)Endocrine Cancers Endocrine Neoplasia Esophageal (GI)Gastric/Stomach (GI)Gastrointestinal (GI) (Multiple Types)General Solid Tumors (Multiple Types)GenitoUrinary (GU) (Multiple Types)GEP-NET (NEC)GI Stromal Tumor (GIST)Gynecologic (GYN) (Multiple Types)Head and Neck Cancers Hepatocellular/Liver (GI)Hodgkins Lymphoma Insulinoma Kidney/Renal Cell Carcinoma (GU)Leukemias Lung Lymphomas Melanoma/Skin Cancers Mesothelioma Multiple Myeloma NeuroBlastoma NeuroEndocrine (NEC) (Multiple Types)NeuroEndocrine Carcinoma (NEC)Osteosarcoma Ovarian Ovarian/Primary Peritoneal (GYN)Pancreatic (GI)Paraganglioma (NEC)Penile (GU)Pheochromocytoma (NEC)Pituitary Prostate (GU)Salivary Gland Sarcoma Synovial Carcinoma Testicular (GU)Thymoma Thyroid Unknown Primary Cancers Uterine (GYN)Vulvar (GYN)

Study Status

Enrolling

On Hold

Not Enrolling

Unknown

Last Updated: Tue Nov 19 2024

Pharmaceutical Trials (Site Sponsors)

Investigator Trials

Pharmaceutical & Investigator Trials (Non-Site Sponsors)

🇸🇪

NCT06639191

A Phase 1 Prospective, Open-label, First-in-human Study to Evaluate the Safety, Tolerability and Biodistribution of [177Lu]Lu-AKIR001 and Its Anti-tumour Effect in Adult Patients With CD44v6 Expressing Solid Tumours

The goal of this clinical trial is to evaluate the safety and tolerability of increasing doses of [177Lu]Lu-AKIR001, both in relation to tolerable activity of lutetium-177 and the absorbed protein mass dose of AKIR-001 in patients with irresectable or metastatic CD44v6-expressing solid malignancies for whom no reasonable systemic treatment options are be available.

© 2021 XCancer Software LLC

Contact XCancer: 402-991-8468